Philips Launches Azurion with FlexArm to Set New Standard for the Future of Image-Guided Procedures

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced Azurion with FlexArm, to set a new standard for patient imaging and positioning flexibility for image-guided procedures.

During increasingly complex interventions, clinicians need to quickly and easily visualize critical anatomy and identify changes to the patient during the procedure. Azurion with FlexArm includes a set of innovations that makes it easier for the clinician to perform imaging across the whole patient in both 2D and 3D. As the clinician moves the system, the image beam automatically maintains alignment with the patient, allowing more consistent visualization and enabling them to keep their focus on the treatment.

"With FlexArm, Philips' engineers have overcome near-impossible geometric and mechanical barriers to enable clinicians to achieve clinical excellence in image-guided therapy," said Barry T. Katzen, MD, founder and Chief Medical Executive of the Miami Cardiac & Vascular Institute, Baptist Health South Florida (U.S.). "FlexArm enables us to dramatically optimize procedures around the patient: we can get the optimal view of what's going on inside the patient without encumbering all of the clinicians that are working around the table. The result is an innovation that’s not only clinically important but also very simple and intuitive to use - a critical factor in the heat of a complex procedure."

The range and complexity of diseases that can be treated with minimally invasive procedures continues to expand. Correspondingly, the procedures themselves are also becoming more complex, requiring more physicians from different disciplines to be at the patient’s tableside, working together in a highly coordinated way. As a result, the clinical team is required to carry out increasingly challenging procedures in a highly constrained environment.

Azurion with FlexArm's innovative design provides exceptional flexibility and intuitive control. Powered by a unique smart kinematic engine, the system moves on eight different axes, all controlled with its single 'Axsys' controller. Simulation tests with clinicians have demonstrated the system's potential to significantly reduce the repositioning of the patient, staff and equipment to improve access for minimally invasive procedures, including those that enter the body through the patient's wrist ('radial access'), and to reduce the risk of unintentional pulling of wires and tubes, as well as significant time savings [1]. The system is ideally suited for Hybrid ORs that cater to multiple specialties in one room, such as a combination of surgical and endovascular procedures.

"Two years on from its launch, Azurion is now established as our leading platform for interventional procedures, favored by clinicians for its intuitive, seamless approach that enables them to focus on treating the patient, and by hospital administrators for its positive impact on productivity and efficiency," said Ronald Tabaksblat, Business Leader Image Guided Therapy Systems, Philips. "FlexArm is the natural next step in our Azurion innovation journey, combining clinical and operational benefits to improve patient care and reduce costs, while opening up opportunities for new image-guided procedures as the field continues grow."

Azurion with FlexArm is the latest innovation in Philips' unique portfolio of systems, smart devices, software and services in image-guided therapy, which combine to provide healthcare providers with sophisticated, procedure-oriented solutions. As the range of diseases that can be treated with minimally invasive procedures continues to expand and the procedures themselves become more efficient, the patient's treatment experience continues to improve. They experience less trauma, and as a result their stay in hospital can be dramatically reduced - often returning home after one night in hospital, and for some procedures even leaving the hospital on the same day.

Since its global launch in February 2017, over 450.000 patients have been treated in more than 80 countries using a Philips Azurion system. The Philips Azurion 7 C20 with FlexArm is CE marked and has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2017 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries.

1. Uselab simulation test with 15 clinicians.

Most Popular Now

Welcome Evo, Generative AI for the Genom…

Brian Hie runs the Laboratory of Evolutionary Design at Stanford, where he works at the crossroads of artificial intelligence and biology. Not long ago, Hie pondered a provocative question: If...

Research Study Shows the Cost-Effectiven…

Earlier research showed that primary care clinicians using AI-ECG tools identified more unknown cases of a weak heart pump, also called low ejection fraction, than without AI. New study findings...

Remote Telemedicine Tool Found Highly Ac…

Collecting images of suspicious-looking skin growths and sending them off-site for specialists to analyze is as accurate in identifying skin cancers as having a dermatologist examine them in person, a...

New Study Reveals Why Organisations are …

The slow adoption of blockchain technology is partly driven by overhyped promises that often obscure the complex technological, organisational, and environmental challenges, according to research from the University of Surrey...

Almost All Leading AI Chatbots Show Sign…

Almost all leading large language models or "chatbots" show signs of mild cognitive impairment in tests widely used to spot early signs of dementia, finds a study in the Christmas...

Philips Aims to Advance Cardiac MRI Tech…

Royal Philips (NYSE: PHG, AEX: PHIA) and Mayo Clinic announced a research collaboration aimed at advancing MRI for cardiac applications. Through this investigation, Philips and Mayo Clinic will look to...

Deep Learning Model Accurately Diagnoses…

Using just one inhalation lung CT scan, a deep learning model can accurately diagnose and stage chronic obstructive pulmonary disease (COPD), according to a study published today in Radiology: Cardiothoracic...

Shape-Changing Device Helps Visually Imp…

Researchers from Imperial College London, working with the company MakeSense Technology and the charity Bravo Victor, have developed a shape-changing device called Shape that helps people with visual impairment navigate...

Bayer Acquires HiDoc Technologies and Ca…

Bayer is today announcing that it plans to acquire HiDoc Technologies GmbH in the first quarter of 2025 and to start commercialization of the digital health application, Cara Care®. Cara...

AI-Based Chatbot Created for Bioimage An…

Scientists from Universidad Carlos III de Madrid (UC3M), together with a research team from Ericsson and the KTH Royal Institute of Technology in Sweden, have developed an artificial intelligence-based software...

Analyzing Multiple Mammograms Improves B…

A new study from Washington University School of Medicine in St. Louis describes an innovative method of analyzing mammograms that significantly improves the accuracy of predicting the risk of breast...

Emotional Cognition Analysis Enables Nea…

A joint research team from the University of Canberra and Kuwait College of Science and Technology has achieved groundbreaking detection of Parkinson's disease with near-perfect accuracy, simply by analyzing brain...